Stock Ratings / Health Care / KRSA / insiders

OMER (46) AAPG (57) DMRA (47) KARD (61) ⌘ Pro Terminal →

Korsana Biosciences Inc. (KRSA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$30.22 +0.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $30.18

Korsana Biosciences Inc. (KRSA) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $1.38B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $30.18 (-0.12%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KRSA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY KRSA SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+9/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$33.92-4.5% Next Q

Q2 (-2Q)

Grade E$32.38-3.3% Next Q

Q3 (-1Q)

Grade E$31.31-3.5% Next Q

Current

Grade E$30.22-8.9% Hist 90D α

Trajectory: D (41) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KRSA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KRSA currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($31.09) and Max Pain ($31.73) forces dealer call-delta covering toward $62.33.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KRSA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “KRSA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

KRSA Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (KRSA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on KRSA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KRSA)

✓Walkthrough of KRSA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KRSA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +30.43%📐 HORIZONTAL RANGE

2026-10-30O $30.00H $30.27L $29.29C $30.22VOL 104.2K

RES: $43.59SUP: $19.35SMA50: $31.09SMA200: $21.95

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KRSA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KRSA Butterfly Map → + Track KRSA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +3.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KRSA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KRSA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KRSA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KRSA)

Health Care Rank #859 of 1016 ⚔️ OMER vs KRSA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KRSA vs. OMER, AAPG, DMRA, KARD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Korsana Biosciences Inc. (KRSA) ranks #859 by composite RQD confidence (33/100, grade E) and #315 by equity capitalization ($1.38B). Within this direct 5-issuer industry benchmark cohort, KRSA leads on earnings valuation at N/A trailing P/E, while KRSA leads on capital efficiency and profitability with -5.7% ROIC and — gross margin. KARD currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with KRSA at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KRSA ACTIVE Korsana Biosciences Inc.	E	33/100	—	—	-5.7%	+0.37%	$1.38B	Benchmark Subject
OMER Omeros Corporation	D	46/100	—	—	-35.0%	+5.98%	$1.37B	/omer-vs-krsa →
AAPG Ascentage Pharma Group International American Depository Shares	D+	57/100	—	—	—	-0.70%	$1.39B	/aapg-vs-krsa →
DMRA Damora Therapeutics Inc.	D	47/100	—	—	-35.0%	+1.85%	$1.36B	/dmra-vs-krsa →
KARD Kardigan Inc.	C-	61/100	—	—	—	+4.22%	$1.34B	/kard-vs-krsa →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001755237

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Korsana Biosciences Inc. (KRSA) reported GAAP revenue of $2.1M (+3.7% vs. FY2024 revenue of $2.0M ) , GAAP net income of -$3.5M, operating cash flow of -$3.3M, and free cash flow of -$3.3M (+23.5% YoY). On the balance sheet, KRSA closed FY2025 with $10.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.1M	-$3.5M	-$3.3M	-$3.3M	$10.0M	—
FY2024 (FY)	2024-12-31	$2.0M	-$3.1M	-$4.3M	-$4.3M	$9.6M	—
FY2023 (FY)	2023-12-31	$0	-$5.3M	-$21.2M	-$21.2M	—	—

3. KRSA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KRSA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Korsana Biosciences Inc. (NASDAQ: KRSA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $30.22 (+0.37% 1D, market cap $1.38B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, KRSA ranks #859 in composite RQD confidence.

How does KRSA compare to OMER and AAPG in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KRSA carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -5.7%. By comparison, OMER (Omeros Corporation) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $1.37B) and AAPG (Ascentage Pharma Group International American Depository Shares) posts a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $1.39B). Among the 5-stock peer group, KRSA leads on earnings multiple (N/A) while KRSA leads on capital efficiency (-5.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KRSA?

Per KRSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001755237), Korsana Biosciences Inc. generated $2.1M in revenue (+3.7% YoY), -$3.5M in net income, and -$3.3M in free cash flow against $10.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KRSA trading relative to its 50-day, 200-day, and 52-week technical levels?

KRSA last traded at $30.22 (+0.37% on volume of 138,999 shares), positioning the stock -2.80% below its 50-day simple moving average ($31.09) and +37.68% above its 200-day simple moving average ($21.95). Across its 52-week range of $7.19 to $59.36, KRSA sits at the 44.1% percentile with a 14-day RSI of 45.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($26.44 to $34.00).

KRSA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are KRSA insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies KRSA leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: KRSA RQD Cockpit KRSA 12M Forecast KRSA Earnings & Move KRSA Dividends & DRIP KRSA Insiders & 13F KRSA Whale Options KRSA Profit Sankey KRSA News & Why